Journal
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Volume 10, Issue 4, Pages 283-292Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152010791162298
Keywords
Anticancer drug; Dithiocarbamate; Gold compounds; Metallodrug; Nephrotoxicity; Proteasome inhibitor; Reactive oxygen species (ROS); Thioredoxin reductase (TrxR)
Categories
Funding
- EU [MERG-CT-2007-204828]
- Ministry of Health
- Ann Karmanos Cancer Institute [2009]
- National Cancer Institute [NCI 1R21CA139386-01]
- Consorzio Interuniversitario di Ricerca in Chimica dei Metalli nei Sistemi Biologici (CIRCMSB to DF)
Ask authors/readers for more resources
In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available